Advances in the design of a multipurpose fragment screening library

Expert Opinion on Drug Discovery

Volumn 8, Issue 5, 2013, Pages 597-606

  Wilde, Felix ^a   Link, Andreas ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

Author keywords

Decoupled PK and PD; Druggability; Fragment based drug design; Fragment based lead discovery; Halogen bonds; HEFLibs; High throughput screening; Ligand efficiency; Lipophilic ligand efficiency; Pentafluoro sulfanyl; Pharmacophore linked fragment virtual screening

Indexed keywords

ANTITRYPANOSOMAL AGENT; BENZIMIDAZOLE DERIVATIVE; CYCLOPHILIN INHIBITOR; HALOGEN; INTERLEUKIN 2; MEFLOQUINE; NATURAL PRODUCT; UBIQUINOL CYTOCHROME C REDUCTASE;

AFFINITY CHROMATOGRAPHY; BINDING SITE; COVALENT BOND; CYCLIZATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; FLUORINE NUCLEAR MAGNETIC RESONANCE; FRAGMENT BASED LEAD DISCOVERY; GOLD STANDARD; HYBRIDIZATION; HYDROGEN BOND; HYDROPHILICITY; ISOTHERMAL TITRATION CALORIMETRY; LIPOPHILICITY; MOLECULAR LIBRARY; MOLECULAR RECOGNITION; MOLECULAR WEIGHT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; REVIEW; STATIC ELECTRICITY; X RAY CRYSTALLOGRAPHY;

EID: 84876769935     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2013.780022     Document Type: Review

References (30)

1. Murray CW, Verdonk ML, Rees DC. Experiences in fragment-based drug discovery. Trends Pharmacol Sci 2012;33:224-32
2. Philpott M, Yang J, Tumber T, et al. Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol BioSyst 2011;7:2899-908
3. Arkin MR. Fragment-based discovery of modulators for PPI and allosteric enzymes. EFMC, Berlin; 2012. p. 45
4. Baker M. Fragment-based lead discovery grows up. Nat Rev Drug Discov 2013;12:5-7
5. de Graaf C. Fragments, fits, fingerprints: structure-based virtual screening for fragment-like GPCR ligands. EFMC, Berlin; 2012. p. 48
6. Nair PC, Malde AK, Drinkwater N, Mark AE. Missing fragments: detecting cooperative binding in fragment-based drug design. ACS Med Chem Lett 2012;3:322-6
7. Jordan JB, Poppe L, Xia X, et al. Fragment based drug discovery: practical implementation based on 19F NMR spectroscopy. J Med Chem 2012;55:678-87
8. Chen D, Errey JC, Heitman LH, et al. Fragment screening of GPCRs using biophysical methods: identification of ligands of the adenosine A2A receptor with novel biological activity. ACS Chem Biol 2012;7:2064-73
9. Hao GF, Wang F, Li H, et al. Computational discovery of picomolar Q(o) site inhibitors of cytochrome bc1 complex. J Am Chem Soc 2012;134:11168-76
10. Jhoti H. Fragment-based drug discovery - a decade of thinking small. EFMC, Berlin; 2012. p. 21
11. Pihan E, Colliandre L, Guichou JF, Douguet D. e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. Bioinformatics 2012;28:1540-1
12. Chidley C, Haruki H, Pedersen MG, et al. A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. Nat Chem Biol 2011;7:375-83 . The FDA approved anti-inflammatory drug sulfasalazine has been shown to be a sepiapterin reductase inhibitor: orphan targets adressed by old compounds are fascinating starting points in drug design.
13. Micheli F, Andreotti D, Braggio S, Checchia A. A specific and direct comparison of the trifluoromethyl and pentafluoro sulfanyl groups on the selective dopamine D(3) antagonist 3-(3- {[4-methyl-5-(4-methyl-1,3-oxazol-5-yl) - 4H-1,2,4-triazol-3-yl]thio}propyl)-1- phenyl-3-azabicyclo[3.1.0]hexane template. Bioorg Med Chem Lett 2010;20:4566-8 . Trifluoromethyl and pentafluoro sulfanyl groups are shown to be two of a kind and can be used for improved lead optimization.
14. Larsen T, Link A. A timely reassessment of early prediction in the bioavailability of orally administered drugs. Angew Chem Int Ed Engl 2005;44:4432-4 . Several more or less fruitful attemps to add descriptors to the Ro5 are discussed.
15. Dow GS, Milner EE, Wipf P, Mo T. Derivatives of mefloquine and associated methods for making and using. WO2010144434; 2010, 128pp
16. Stump B, Eberle C, Schweizer WB, et al. Pentafluorosulfanyl as a novel building block for enzyme inhibitors: trypanothione reductase inhibition and antiprotozoal activities of diarylamines. ChemBioChem 2009;10:79-83
17. Wilcken R, Liu X, Zimmermann MO, et al. Halogen-enriched fragment libraries as leads for drug rescue of mutant p53. J Am Chem Soc 2012;134:6810-18
18. Congreve M, Carr R, Murray C, Jhoti H. A 'rule of three' for fragment-based lead discovery? Drug Discov Today 2003;8:876-7
19. Amidon GL, Lennernas H, Shah VP, Crison Jr. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 1995;12:413-20
20. Alelyunas YW, Empfield JR, McCarthy D, et al. Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Bioorg Med Chem Lett 2010;20:7312-16
21. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000;44:235-49
22. Ishikawa M, Hashimoto Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J Med Chem 2011;54:1539-54 . Astonishing examples are given in which the introduction of lipophilic substituents leads to derivatives with better solubility in water.
23. Over B, Wetzel S, Grutter C, et al. Natural-product-derived fragments for fragment-based ligand discovery. Nat Chem 2012;5:21-8
24. Spinks D, Torrie LS, Thompson S, et al. Design, synthesis and biological evaluation of Trypanosoma brucei trypanothione synthetase inhibitors. Chem Med Chem 2012;7:95-106
25. Brand S, Cleghorn LA, McElroy SP, et al. Discovery of a novel class of orally active trypanocidal N-myristoyltransferase inhibitors. J Med Chem 2012;55:140-52
26. Guan Y, Bissantz C, Bergstrom DE, Link A. 1,2,4-Trisubstituted cyclopentanes as platforms for diversity. Arch Pharm (Weinheim, Ger) 2012;345:677-86 . Slim and shapely, tereochemically defined, sp3-rich core fragments for the construction of fragment libraries are suggested.
27. Mortenson PN, Murray CW. Assessing the lipophilicity of fragments and early hits. J Comput-Aided Mol Des 2011;25:663-7 . A refined view on lipophilicity assessment of fragments is given.
28. Rees D. LE, LLE and FBDD. EFMC, Berlin; 2012. p. 35
29. Meiby E, Knapp S, Elkins JM, Ohlson S. Fragment screening of cyclin G-associated kinase by weak affinity chromatography. Anal Bioanal Chem 2012;404:2417-25
30. Kamper C, Korpis K, Specker E, et al. Sustainable synthesis and automated deposition: an accessible discovery screening library of fragment-like purines. Mol Divers 2012;16:541-51